Prostate Cancer Foundation of Chicago recently published a study in the journal Cancer in collaboration with Harvard Radiation Oncology Program and Dana-Farber Cancer Institute. The study assessed the impact of race on the risk of death from all causes and from prostate cancer alone among men actively treated for favorable-risk prostate cancer.
To make prostate cancers shrink or grow more slowly, androgen-suppression hormone therapy (ADT) is often added to brachytherapy radiation therapy as the standard of care for men with intermediate- and high-risk prostate cancer. Intermediate-risk prostate cancer can be further classified as favorable- or unfavorable-risk disease
African Americans are more likely to be affected by concurrent chronic diseases— diabetes, coronary artery disease, previous myocardial infarction or congestive heart failure—which may interact with hormone therapy and reduce its benefits. This new research demonstrates that adding hormone therapy to treatment received by African American men for favorable intermediate risk prostate cancer is actually associated with shortened survival, when compared to non-African Americans with the same stage prostate cancer.
These findings will help physicians determine whether to add hormone therapy to radiation therapy for their African American patients, possibly reserving hormone therapy for cases of higher risk prostate cancers. Read more about the study, Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer. Further information on prostate cancer risk and detection includes special recommendations for African American men and is available at Prostate Cancer Foundation of Chicago’s educational infographic, The Importance of Prostate Cancer Screening.